KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 107 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q1 2021. The put-call ratio across all filers is 1.40 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,235,059 | +70.7% | 71,103 | +38.3% | 0.01% | +66.7% |
| Q2 2023 | $723,628 | -24.4% | 51,394 | -38.8% | 0.01% | -33.3% |
| Q3 2021 | $957,000 | +61.4% | 83,983 | +97.3% | 0.01% | +80.0% |
| Q2 2021 | $593,000 | -44.0% | 42,571 | -25.6% | 0.01% | -50.0% |
| Q1 2021 | $1,059,000 | +5.8% | 57,230 | +1.1% | 0.01% | -9.1% |
| Q4 2020 | $1,001,000 | +208.0% | 56,627 | +48.3% | 0.01% | +266.7% |
| Q3 2019 | $325,000 | -39.7% | 38,173 | -4.0% | 0.00% | -25.0% |
| Q2 2019 | $539,000 | -33.0% | 39,773 | -10.8% | 0.00% | -33.3% |
| Q1 2019 | $805,000 | -21.4% | 44,568 | +22.3% | 0.01% | -25.0% |
| Q4 2018 | $1,024,000 | +44.0% | 36,453 | +30.7% | 0.01% | +60.0% |
| Q3 2018 | $711,000 | +91.6% | 27,893 | +30.3% | 0.01% | +150.0% |
| Q2 2018 | $371,000 | – | 21,402 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Spearhead Capital Advisors, LLC | 202,580 | $2,601,000 | 2.82% |
| Lion Point Capital, LP | 480,000 | $5,140,000 | 1.13% |
| HHLR ADVISORS, LTD. | 2,920,023 | $37,493,000 | 0.99% |
| TANG CAPITAL MANAGEMENT LLC | 600,000 | $7,704,000 | 0.94% |
| Rubric Capital Management LP | 1,446,107 | $18,568,000 | 0.94% |
| AlphaCentric Advisors LLC | 43,000 | $552,000 | 0.57% |
| RICE HALL JAMES & ASSOCIATES, LLC | 749,933 | $9,629,000 | 0.56% |
| Parkman Healthcare Partners LLC | 126,192 | $1,620,000 | 0.46% |
| Birchview Capital, LP | 30,000 | $385,000 | 0.27% |
| Baker Brothers Advisors | 2,799,577 | $35,947,000 | 0.24% |